Production of recombinant proteins from protozoan parasites.
Although the past decade has witnessed sequencing from an increasing number of parasites, modern high-throughput DNA sequencing technologies have the potential to generate complete genome sequences at even higher rates. Along with the discovery of genes that might constitute potential targets for chemotherapy or vaccination, the need for novel protein expression platforms has become a pressing matter. In addition to reviewing the advantages and limitations of the currently available and emerging expression systems, we discuss novel approaches that could overcome current limitations, including the 'pseudoparasite' concept, an expression platform in which the choice of the surrogate organism is based on its phylogenetic affinity to the target parasite, while taking advantage of the whole engineered organism as a vaccination adjuvant.
Fernández-Robledo
José A
JA
Department of Microbiology and Immunology, University of Maryland School of Medicine, IMET, 701 E. Pratt Street, Suite 236, Baltimore, MD 21202-3101, USA. JFernandez-Robledo@som.umaryland.edu <JFernandez-Robledo@som.umaryland.edu>
Vasta
Gerardo R
GR
D002474:Cell-Free System; D056890:Eukaryota / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D011387:Prokaryotic Cells / Q000378:metabolism; D015800:Protozoan Proteins / Q000096:biosynthesis* / Q000276:immunology; D016052:Protozoan Vaccines / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000276:immunology
D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D011994:Recombinant Proteins